A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6

NCT06091930 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastrointestinal Cancer
Lung Cancer
Pancreatic Cancer
Colorectal Cancer
Head and Neck Cancer
Liver Cancer

Interventions

DRUG: BI 765049
DRUG: Ezabenlimab

Sponsor

Boehringer Ingelheim